[{"id":"f548789f-e984-493e-8c25-7196761bc8df","acronym":"","url":"https://clinicaltrials.gov/study/NCT07153952","created_at":"2025-09-06T13:40:49.515Z","updated_at":"2025-09-06T13:40:49.515Z","phase":"Phase 1/2","brief_title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","source_id_and_acronym":"NCT07153952","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-09-04"},{"id":"65e873c4-e41a-4522-8b0f-ce3ec9de207d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00609791","created_at":"2021-01-18T02:15:51.515Z","updated_at":"2025-02-25T14:06:39.505Z","phase":"Phase 2","brief_title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer","source_id_and_acronym":"NCT00609791","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/11/2008","start_date":" 02/11/2008","primary_txt":" Primary completion: 10/25/2011","primary_completion_date":" 10/25/2011","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2025-02-19"},{"id":"9cfc6cab-bd14-4a27-8da2-14e1f08db131","acronym":"","url":"https://clinicaltrials.gov/study/NCT01463072","created_at":"2021-01-18T06:05:14.850Z","updated_at":"2025-02-25T13:59:58.723Z","phase":"Phase 2","brief_title":"Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT01463072","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/19/2012","start_date":" 06/19/2012","primary_txt":" Primary completion: 05/17/2017","primary_completion_date":" 05/17/2017","study_txt":" Completion: 06/17/2025","study_completion_date":" 06/17/2025","last_update_posted":"2025-02-19"},{"id":"739da834-c39c-4ec9-a53c-9176d039bf87","acronym":"WSG-ADAPT-TN","url":"https://clinicaltrials.gov/study/NCT01815242","created_at":"2021-01-18T08:03:29.975Z","updated_at":"2025-02-25T14:34:04.747Z","phase":"Phase 2","brief_title":"Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer","source_id_and_acronym":"NCT01815242 - WSG-ADAPT-TN","lead_sponsor":"West German Study Group","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 336","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-11-20"},{"id":"14077522-c4f9-49b8-a790-5ed5d6ceade7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928612","created_at":"2025-03-03T15:59:29.814Z","updated_at":"2025-03-03T15:59:29.814Z","phase":"Phase 1","brief_title":"A Study of CBP-1018 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04928612","lead_sponsor":"Coherent Biopharma (Suzhou) Co., Ltd.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1018"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"d1922c38-e216-43b5-b703-ed22fcdc9fe9","acronym":"PLATINUM","url":"https://clinicaltrials.gov/study/NCT06115499","created_at":"2023-11-03T21:12:37.038Z","updated_at":"2024-07-02T16:35:01.784Z","phase":"Phase 2/3","brief_title":"The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT06115499 - PLATINUM","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 01/15/2029","primary_completion_date":" 01/15/2029","study_txt":" Completion: 12/09/2029","study_completion_date":" 12/09/2029","last_update_posted":"2024-05-23"},{"id":"03e89ab8-dacb-455b-84eb-7a4c304f5cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06338657","created_at":"2024-03-29T14:40:53.948Z","updated_at":"2024-07-02T16:35:02.933Z","phase":"Phase 1","brief_title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","source_id_and_acronym":"NCT06338657","lead_sponsor":"University of Southern California","biomarkers":" PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nanoencapsulated paclitaxel (FID-007)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-17"},{"id":"cadff643-56b0-4e97-baf3-eaa0cd1d40bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05693844","created_at":"2023-01-23T16:00:11.670Z","updated_at":"2024-07-02T16:35:04.514Z","phase":"Phase 1/2","brief_title":"Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05693844","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • CD40 ligand expressing MSLN-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-10"},{"id":"d5620614-b21c-4e48-b7e1-c4792175d95e","acronym":"APEX-01","url":"https://clinicaltrials.gov/study/NCT04662580","created_at":"2023-11-22T19:16:10.387Z","updated_at":"2024-07-02T16:35:04.424Z","phase":"Phase 1","brief_title":"ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04662580 - APEX-01","lead_sponsor":"Ambrx, Inc.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • JNJ-8177"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-05-10"},{"id":"0ccb44d0-a3ca-40d3-9e1b-fba72ac53b19","acronym":"","url":"https://clinicaltrials.gov/study/NCT06182072","created_at":"2023-12-26T16:18:21.142Z","updated_at":"2024-07-02T16:35:07.619Z","phase":"Phase 1","brief_title":"ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06182072","lead_sponsor":"ProDa BioTech, LLC","biomarkers":" PKM","pipe":"","alterations":" ","tags":["PKM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-04-25"},{"id":"75f5efdb-b599-4425-8625-746ee81cb687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05285358","created_at":"2022-03-17T11:53:12.288Z","updated_at":"2024-07-02T16:35:15.806Z","phase":"Phase 1","brief_title":"Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases","source_id_and_acronym":"NCT05285358","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/19/2022","start_date":" 09/19/2022","primary_txt":" Primary completion: 10/11/2028","primary_completion_date":" 10/11/2028","study_txt":" Completion: 10/11/2028","study_completion_date":" 10/11/2028","last_update_posted":"2024-03-07"},{"id":"92d049be-73d0-4ea0-8eaf-f039e76f1242","acronym":"ETNA","url":"https://clinicaltrials.gov/study/NCT01822314","created_at":"2021-01-18T08:04:39.209Z","updated_at":"2024-07-02T16:35:15.989Z","phase":"Phase 3","brief_title":"Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer","source_id_and_acronym":"NCT01822314 - ETNA","lead_sponsor":"Fondazione Michelangelo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 632","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2024-03-07"},{"id":"0ac61cbf-3e9f-4af1-95a4-5ca408d4fa59","acronym":"NeoTRIPaPDL1","url":"https://clinicaltrials.gov/study/NCT02620280","created_at":"2021-01-18T12:43:52.463Z","updated_at":"2024-07-02T16:35:16.015Z","phase":"Phase 3","brief_title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","source_id_and_acronym":"NCT02620280 - NeoTRIPaPDL1","lead_sponsor":"Fondazione Michelangelo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 278","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/07/2024","study_completion_date":" 01/07/2024","last_update_posted":"2024-03-06"},{"id":"afef0721-8e8b-4e9e-b3e0-4b699e32e056","acronym":"OPERA","url":"https://clinicaltrials.gov/study/NCT03326102","created_at":"2021-01-18T16:25:31.533Z","updated_at":"2024-07-02T16:35:19.038Z","phase":"Phase 2","brief_title":"Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer","source_id_and_acronym":"NCT03326102 - OPERA","lead_sponsor":"Daehwa Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Liporaxel (paclitaxel oral)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 07/06/2018","start_date":" 07/06/2018","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2024-02-16"},{"id":"68137f3c-4ca8-416a-9aa1-8fb6f113f511","acronym":"HNC-SYSU-005","url":"https://clinicaltrials.gov/study/NCT06143761","created_at":"2023-11-22T16:16:36.669Z","updated_at":"2024-07-02T16:35:28.260Z","phase":"","brief_title":"Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer","source_id_and_acronym":"NCT06143761 - HNC-SYSU-005","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-11-22"},{"id":"ae9f6690-c437-43f1-a5a6-13ec7cf09e5f","acronym":"ZV0203-001CN","url":"https://clinicaltrials.gov/study/NCT05423977","created_at":"2022-06-22T00:55:16.188Z","updated_at":"2024-07-02T16:35:28.620Z","phase":"Phase 1","brief_title":"Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT05423977 - ZV0203-001CN","lead_sponsor":"Hangzhou Adcoris Biopharmacy Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADC2122"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 05/05/2023","primary_completion_date":" 05/05/2023","study_txt":" Completion: 07/07/2024","study_completion_date":" 07/07/2024","last_update_posted":"2023-11-20"},{"id":"db8e8daa-9572-4cc7-8061-60fb432200a8","acronym":"SC9/ABX","url":"https://clinicaltrials.gov/study/NCT04528680","created_at":"2021-01-18T21:41:07.181Z","updated_at":"2025-02-25T14:29:32.725Z","phase":"Phase 1/2","brief_title":"Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma","source_id_and_acronym":"NCT04528680 - SC9/ABX","lead_sponsor":"Northwestern University","biomarkers":" IDH1 • SSR3","pipe":" | ","alterations":" IDH wild-type • IDH1 R132","tags":["IDH1 • SSR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/29/2020","start_date":" 10/29/2020","primary_txt":" Primary completion: 09/10/2024","primary_completion_date":" 09/10/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-11-15"},{"id":"05bf4a3f-d394-41f6-a269-f8d832b74ef9","acronym":"ProglumidePanc","url":"https://clinicaltrials.gov/study/NCT06017323","created_at":"2023-08-30T14:08:49.945Z","updated_at":"2024-07-02T16:35:31.792Z","phase":"Phase 1","brief_title":"Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT06017323 - ProglumidePanc","lead_sponsor":"Georgetown University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-10-25"},{"id":"4fd49257-b582-4a96-93a6-ea4a6b942a9c","acronym":"GAIN-1","url":"https://clinicaltrials.gov/study/NCT01470417","created_at":"2021-01-18T06:07:30.606Z","updated_at":"2024-07-02T16:35:39.332Z","phase":"Phase 2","brief_title":"Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT01470417 - GAIN-1","lead_sponsor":"University of Florida","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2023-08-22"},{"id":"55fc9994-8b85-42e1-a322-c1481d787dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03602079","created_at":"2021-01-17T17:58:25.852Z","updated_at":"2024-07-02T16:35:41.099Z","phase":"Phase 1/2","brief_title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","source_id_and_acronym":"NCT03602079","lead_sponsor":"Klus Pharma Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sertaly (trastuzumab botidotin)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 01/12/2022","primary_completion_date":" 01/12/2022","study_txt":" Completion: 01/12/2022","study_completion_date":" 01/12/2022","last_update_posted":"2023-08-03"},{"id":"beebcd86-9983-496c-baec-6ba92e35b0ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003546","created_at":"2021-01-18T14:46:28.152Z","updated_at":"2024-07-02T16:35:45.549Z","phase":"Phase 1","brief_title":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial","source_id_and_acronym":"NCT03003546","lead_sponsor":"Mayo Clinic","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 05/16/2023","primary_completion_date":" 05/16/2023","study_txt":" Completion: 05/16/2023","study_completion_date":" 05/16/2023","last_update_posted":"2023-06-15"},{"id":"166b395a-b81a-47cb-b2b8-aeb36409539d","acronym":"SNAP","url":"https://clinicaltrials.gov/study/NCT01746225","created_at":"2021-01-18T07:39:14.213Z","updated_at":"2024-07-02T16:35:46.731Z","phase":"Phase 2","brief_title":"Schedules of Nab-Paclitaxel in Metastatic Breast Cancer","source_id_and_acronym":"NCT01746225 - SNAP","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 258","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 03/16/2023","study_completion_date":" 03/16/2023","last_update_posted":"2023-06-01"},{"id":"1f49581a-ccdf-45d6-b014-9fa49967e11d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00499291","created_at":"2021-01-18T01:47:16.522Z","updated_at":"2024-07-02T16:35:47.102Z","phase":"","brief_title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors","source_id_and_acronym":"NCT00499291","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CYP2C8","pipe":"","alterations":" ","tags":["CYP2C8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-05-25"},{"id":"8d23040c-eb5b-46ae-b239-6ec3069ea4b5","acronym":"SEPION","url":"https://clinicaltrials.gov/study/NCT04257448","created_at":"2021-01-18T20:41:34.546Z","updated_at":"2025-02-25T14:29:02.158Z","phase":"Phase 1/2","brief_title":"Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04257448 - SEPION","lead_sponsor":"GWT-TUD GmbH","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • lenalidomide • azacitidine • albumin-bound paclitaxel • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-01"}]